Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Pharmacodynamic Studies of Methylphenidate ER in Pediatric ADHD
NCT02536105Completed
- Sponsor
- Massachusetts General Hospital
- Start
- May 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (4 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Permanent Product Measure of Performance at 12 hours, Swanson, Kotkin, Agler, M-Flynn, and Pelham Rating Scale at 12 hours and 2 more. Started May 2016; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02536105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02536105.